Interestingly, Eser et al. demonstrated that KRAS downstream effectors exhibit tissue-specificity and provided evidence that PI3K/PDK1 is a suitable target in pancreatic ductal adenocarcinoma (PDAC) [117]. The gene discussed is PDK1; the disease is pancreatic ductal adenocarcinoma.